Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort

[1] Marini JC(2017)Osteogenesis imperfecta Nat Rev Dis Primers 3 17052-1671

[2] Forlino A(2016)Osteogenesis imperfecta Lancet. 387 1657-952

[3] Bachinger HP(1998)Cyclic administration of pamidronate in children with severe osteogenesis imperfecta N Engl J Med 339 947-460

[4] Bishop NJ(2006)Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta J Pediatr 148 456-1295

[5] Byers PH(2016)Bisphosphonate therapy for osteogenesis imperfecta Cochrane Database Syst Rev 10 CD005088-831

[6] Paepe A(2011)Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern? J Bone Joint Surg Br 93 1289-323

[7] Forlino A(2006)Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821-161

[8] Marini JC(1999)OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature. 397 315-1470

[9] Glorieux FH(2009)Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153-3126

[10] Bishop NJ(2012)Denosumab treatment for fibrous dysplasia J Bone Miner Res 27 1462-e202

[1] Marini JC(2017)Osteogenesis imperfecta Nat Rev Dis Primers 3 17052-1671

[2] Forlino A(2016)Osteogenesis imperfecta Lancet. 387 1657-952

[3] Bachinger HP(1998)Cyclic administration of pamidronate in children with severe osteogenesis imperfecta N Engl J Med 339 947-460

[4] Bishop NJ(2006)Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta J Pediatr 148 456-1295

[5] Byers PH(2016)Bisphosphonate therapy for osteogenesis imperfecta Cochrane Database Syst Rev 10 CD005088-831

[6] Paepe A(2011)Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern? J Bone Joint Surg Br 93 1289-323

[7] Forlino A(2006)Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821-161

[8] Marini JC(1999)OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature. 397 315-1470

[9] Glorieux FH(2009)Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153-3126

[10] Bishop NJ(2012)Denosumab treatment for fibrous dysplasia J Bone Miner Res 27 1462-e202